Universe Pharmaceuticals Inc
UPC
0 hedge funds and large institutions have $0 invested in Universe Pharmaceuticals Inc in 2026 Q1 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
0.17% less ownership
Funds ownership: 0.17% → 0% (-0.17%)
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $3.6K → $0 (-$3.6K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$3.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| – | -$3.6K | -946 | Closed |
|
UPC Hedge Fund Activity: Q1 2026 in Review
0 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Universe Pharmaceuticals Inc (UPC) for Q1 2026, worth a combined $0 — down 100% from $3.6K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of UPC and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was UBS Group, exiting entirely with an estimated $3.6K sold.
- 0 institutional investors held Universe Pharmaceuticals Inc (UPC) as of Q1 2026, down from 1 in Q4 2025.
- Funds reported $0 of Universe Pharmaceuticals Inc stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new Universe Pharmaceuticals Inc positions in Q1 2026 and 1 closed out, a net change of -1 holder.
- The largest Universe Pharmaceuticals Inc seller in Q1 2026 was UBS Group, an estimated $3.6K sold.
Based on aggregated 13F filings for Q1 2026.